JP2013544268A5 - - Google Patents

Download PDF

Info

Publication number
JP2013544268A5
JP2013544268A5 JP2013541333A JP2013541333A JP2013544268A5 JP 2013544268 A5 JP2013544268 A5 JP 2013544268A5 JP 2013541333 A JP2013541333 A JP 2013541333A JP 2013541333 A JP2013541333 A JP 2013541333A JP 2013544268 A5 JP2013544268 A5 JP 2013544268A5
Authority
JP
Japan
Prior art keywords
alkyl
group
groups
cycloalkyl
heteroatoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013541333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544268A (ja
JP5853317B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/071410 external-priority patent/WO2012072691A1/en
Publication of JP2013544268A publication Critical patent/JP2013544268A/ja
Publication of JP2013544268A5 publication Critical patent/JP2013544268A5/ja
Application granted granted Critical
Publication of JP5853317B2 publication Critical patent/JP5853317B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013541333A 2010-12-01 2011-11-30 インダニルオキシジヒドロベンゾフラニル酢酸 Expired - Fee Related JP5853317B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP10193382 2010-12-01
EP10193382.8 2010-12-01
EP11154999.4 2011-02-18
EP11154999 2011-02-18
EP11175646.6 2011-07-27
EP11175646 2011-07-27
PCT/EP2011/071410 WO2012072691A1 (en) 2010-12-01 2011-11-30 Indanyloxydihydrobenzofuranylacetic acids

Publications (3)

Publication Number Publication Date
JP2013544268A JP2013544268A (ja) 2013-12-12
JP2013544268A5 true JP2013544268A5 (enExample) 2015-01-22
JP5853317B2 JP5853317B2 (ja) 2016-02-09

Family

ID=45063142

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013541333A Expired - Fee Related JP5853317B2 (ja) 2010-12-01 2011-11-30 インダニルオキシジヒドロベンゾフラニル酢酸

Country Status (10)

Country Link
US (1) US20120302566A1 (enExample)
EP (1) EP2646425B1 (enExample)
JP (1) JP5853317B2 (enExample)
AR (1) AR084050A1 (enExample)
DK (1) DK2646425T3 (enExample)
ES (1) ES2546154T3 (enExample)
HU (1) HUE025363T2 (enExample)
PL (1) PL2646425T3 (enExample)
UY (1) UY33758A (enExample)
WO (1) WO2012072691A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8642585B2 (en) 2012-03-26 2014-02-04 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
US8809376B2 (en) * 2012-04-30 2014-08-19 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
HK1210825A1 (en) 2012-07-11 2016-05-06 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
HK1210144A1 (en) * 2012-11-28 2016-04-15 勃林格殷格翰国际有限公司 New indanyloxydihydrobenzofuranylacetic acids
US20140163025A1 (en) 2012-12-07 2014-06-12 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
WO2014122067A1 (en) 2013-02-06 2014-08-14 Boehringer Ingelheim International Gmbh New indanyloxydihydrobenzofuranylacetic acids
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP3036237A4 (en) * 2013-08-23 2017-01-25 Fujian Haixi Pharmaceuticals Co. Ltd Carboxylic acid compounds in treatment of diabetes mellitus
JP6533778B2 (ja) 2013-09-26 2019-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Gpr40アゴニストとしてのインダニルオキシジヒドロベンゾフラニル酢酸誘導体を調製するための方法および中間体
US10519115B2 (en) 2013-11-15 2019-12-31 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP6441928B2 (ja) * 2013-11-28 2018-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規インダニルオキシフェニルシクロプロパンカルボン酸
EP3076959B1 (en) 2013-12-04 2018-07-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10059667B2 (en) 2014-02-06 2018-08-28 Merck Sharp & Dohme Corp. Antidiabetic compounds
CN105001212B (zh) * 2014-04-16 2018-01-16 江苏柯菲平医药股份有限公司 稠环化合物及其制备方法和应用
WO2015176267A1 (en) 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3177287B1 (en) 2014-08-08 2022-02-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP3177282B1 (en) 2014-08-08 2021-10-06 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
WO2016022446A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
CN104177320B (zh) * 2014-08-27 2016-03-02 广东东阳光药业有限公司 一种脲取代联苯类化合物及其组合物及用途
WO2017172505A1 (en) 2016-03-29 2017-10-05 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
KR102007633B1 (ko) * 2016-12-15 2019-08-06 일동제약(주) 신규 페닐 프로피온 산 유도체 및 이의 용도
EP3558298B1 (en) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Antidiabetic spirochroman compounds
CN110248929B (zh) 2017-01-26 2023-05-12 勃林格殷格翰国际有限公司 苄基氨基吡嗪基环丙烷甲酸、其药物组合物和用途
JP7023969B2 (ja) 2017-01-26 2022-02-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
JP7050791B2 (ja) 2017-01-26 2022-04-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルオキシピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
CN110312714B (zh) 2017-01-26 2022-12-09 勃林格殷格翰国际有限公司 苄基氧基吡嗪基环丙烷甲酸、其药物组合物和用途
EP3580222B1 (en) 2017-02-08 2021-04-07 Boehringer Ingelheim International GmbH Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
US11225471B2 (en) 2017-11-16 2022-01-18 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
KR102708681B1 (ko) 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP4600247A3 (en) 2018-04-19 2025-11-19 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
UA126421C2 (uk) 2018-07-13 2022-09-28 Гіліад Сайєнсіз, Інк. Інгібітори pd-1/pd-l1
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
BR112022006546A2 (pt) 2019-10-07 2022-08-30 Kallyope Inc Agonistas de gpr119
CA3173731A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
CN116323608A (zh) 2020-05-19 2023-06-23 卡尔优普公司 Ampk活化剂
EP4172162A4 (en) 2020-06-26 2024-08-07 Kallyope, Inc. AMPK ACTIVATORS
CN117881670A (zh) * 2021-06-23 2024-04-12 缆图药品公司 制备egfr抑制剂的方法
CN117384086A (zh) * 2023-10-08 2024-01-12 苏州凯瑞医药科技有限公司 一种手性2,2,2-三氟-1-(吡啶-2-基)乙烷-1-醇的合成方法
WO2025140655A1 (en) * 2023-12-30 2025-07-03 Fujian Haixi Pharmaceuticals Co., Ltd. Heteroaryl compounds as multi-target protein kinase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2628103B1 (fr) 1988-03-03 1991-06-14 Roussel Uclaf Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides
EP1559422B1 (en) 2002-11-08 2014-04-30 Takeda Pharmaceutical Company Limited Receptor function controlling agent
JP4594611B2 (ja) * 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
US7557171B2 (en) 2004-12-16 2009-07-07 Exxonmobil Chemical Patents Inc. Halogen substituted metallocene compounds for olefin polymerization
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
KR20080103584A (ko) * 2006-03-30 2008-11-27 아사히 가세이 파마 가부시키가이샤 치환 이환식 환상 유도체 및 그 용도
CL2007001873A1 (es) 2006-06-27 2008-01-04 Takeda Pharmaceutical Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo
WO2008054675A2 (en) * 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
CA2727340A1 (en) 2008-06-25 2009-12-30 Daiichi Sankyo Company, Limited Carboxylic acid compound
US8748462B2 (en) * 2008-10-15 2014-06-10 Amgen Inc. Spirocyclic GPR40 modulators
WO2010143733A1 (en) * 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
US8642585B2 (en) * 2012-03-26 2014-02-04 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids

Similar Documents

Publication Publication Date Title
ES2580481T3 (es) Derivados de aminoquinazolina y sus sales, y métodos de uso
JP6603649B2 (ja) キヌレニン経路の阻害剤
WO2009095872A3 (en) Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors
JP2013510124A5 (enExample)
JP2013505946A5 (enExample)
JP2015501833A5 (enExample)
MX2015015893A (es) 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen.
RU2011108281A (ru) Трипиридилкарбоксамидные антагонисты орексиновых рецепторов
JP2011515483A5 (enExample)
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
JP2020505400A5 (enExample)
JP2014511892A5 (enExample)
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
HRP20170450T1 (hr) Prstenaste n,n′-diariltiouree i n,n′-diariluree kao antagonisti androgenskog receptora, sredstvo protiv raka, postupak njihovog dobivanja i njihove upotrebe
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
AR083069A1 (es) Analogos de nucleotidos sustituidos
JP2017503760A5 (enExample)
JP2011506501A5 (enExample)
PH12015501226A1 (en) Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing the same
JP2015504091A5 (enExample)
AR080802A1 (es) Compuestos de complejos de fe (iii) para el tratamiento y la profilaxis de los sintomas de deficiencia de hierro y anemias por deficiencia de hierro
JP2019535792A5 (enExample)
AR077534A1 (es) Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5
MY197742A (en) Morphinan derivative
JP2017525699A5 (enExample)